On January 22, 2026, Cowen & Co. reaffirmed its Buy rating on Johnson & Johnson and lifted its 12-month price target from $222 to $250, reflecting optimism about JNJ’s product pipeline and long-term growth prospects. This upgrade follows more than a dozen major product launches in 2025 and over 40 regulatory approvals across key markets. In parallel, Zacks Investment Research highlighted Johnson & Johnson in its Earnings ESP model as one of the few medical stocks with a higher likelihood of an earnings surprise, driven by robust demand in oncology and immunology. These positive assessments underscore sustained Wall Street confidence in JNJ’s ability to outperform consensus expectations over the next year.

Johnson & Johnson delivered fourth-quarter revenue of $24.56 billion, up 9.1% year-over-year on a reported basis and 7.1% operationally, led by 27% growth in its Darzalex blood-cancer franchise and double-digit gains in its robotics-assisted surgical systems. Adjusted EPS of $2.46 beat the $2.43 consensus, driven by higher gross margins in pharmaceuticals and disciplined cost management across its MedTech and Innovative Medicine segments. The company generated nearly $20 billion in free cash flow for the full year of 2025, comfortably covering $12.4 billion in dividend payments and supporting a net debt position of approximately $28 billion against $20 billion in cash and marketable securities.

Looking into 2026, Johnson & Johnson projects revenue growth of more than 6% to surpass $100 billion, with adjusted EPS growth of 6%–8%. Key drivers include continued uptake of its Carvykti multiple myeloma treatment, expected to exceed $1 billion in annual sales, and the integration of recent acquisitions such as Intra-Cellular Therapies and Halda Therapeutics, which broaden JNJ’s neuroscience and oncology portfolios. The company also plans to invest approximately $15 billion in R&D, focusing on GABA-modulator neurosteroids and precision immunotherapies, while maintaining its Dividend King status through prudent capital allocation and a target payout ratio below 50%.

Johnson & Johnson retains its AAA credit rating, supported by a conservative leverage ratio and fortress-like liquidity. At year-end 2025, the company held a current ratio above 1.0 and maintained a debt-to-equity ratio near 0.6, underscoring its capacity to fund acquisitions, share repurchases, and dividend increases without compromising financial flexibility. Its 2.4% dividend yield remains nearly double the S&P 500 average, appealing to income-focused investors seeking stability in the healthcare sector’s long-term secular growth themes.